Immuno Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand,the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.
“The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period”
The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service. In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market. The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.
“Research applications segment accounted for the highest CAGR”
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segmentaccounted for the highest growth rate. This can be attributed to the rising prominence of biomarker-based drug development.
“Asia Pacific: The fastest-growing regionimmuno-oncology assays market”
The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global immuno-oncology assays market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
“The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period”
The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service. In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market. The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.
“Research applications segment accounted for the highest CAGR”
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segmentaccounted for the highest growth rate. This can be attributed to the rising prominence of biomarker-based drug development.
“Asia Pacific: The fastest-growing regionimmuno-oncology assays market”
The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
- Thermo Fisher Scientific, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies, Inc. (US)
- Illumina, Inc. (US)
- NanoString Technologies, Inc. (US)
- Sartorius AG (Germany)
- HTG Molecular Diagnostics, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Merck Millipore (US)
- PerkinElmer, Inc. (US)
- Abbott Laboratories, Inc. (US)
- Guardant Health, Inc. (US)
- bioM?rieux SA (France)
- Myriad Genetics, Inc. (US)
- MESO SCALE DIAGNOSTICS, LLC. (US)
- Seegene Inc. (South Korea)
- Bio-Rad Laboratories, Inc. (US)
- Charles River Laboratories, Inc. (US)
- Olink (Sweden)
- ASURAGEN, INC. (US)
- Invivoscribe, Inc. (US)
- Creative Biolabs (US)
- ReachBio LLC (US)
- NMI Technologietransfer GmbH (Germany)
This report provides a detailed picture of the global immuno-oncology assays market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 IMMUNO-ONCOLOGY ASSAYS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 IMMUNO-ONCOLOGY ASSAYS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 4 IMMUNO-ONCOLOGY ASSAYS MARKET: BOTTOM-UP APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 IMMUNO-ONCOLOGY ASSAYS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 HEALTH ASSESSMENT
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE IMMUNO-
ONCOLOGY ASSAYS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 12 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 IMMUNO-ONCOLOGY ASSAYS MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 16 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 17 NGS SEGMENT TO GAIN MARKET SHARE BETWEEN 2021 AND 2026
4.4 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY INDICATION, 2021 VS. 2026
FIGURE 18 LUNG CANCER SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
4.5 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 19 RESEARCH APPLICATIONS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 IMMUNO-ONCOLOGY ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer and growing adoption of targeted therapies
TABLE 1 GLOBAL CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
TABLE 3 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE, 2016 VS. 2017 VS. 2018 (USD MILLION)
5.2.1.2 Increased demand for personalized medicine
TABLE 4 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018
5.2.2 RESTRAINTS
5.2.2.1 Requirement of high capital investments and low cost-benefit ratio
5.2.2.2 Unfavorable regulatory and reimbursement scenario
5.2.2.3 High cost of immunotherapy
TABLE 5 COST OF KEYTRUDA, BY COUNTRY (2018)
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets offer lucrative opportunities
5.2.3.2 Growing significance of companion diagnostics
5.2.4 CHALLENGES
5.2.4.1 Low awareness of cancer immunotherapy
5.3 IMPACT OF COVID-19 ON THE IMMUNO-ONCOLOGY ASSAYS MARKET
5.4 PRICING ANALYSIS
TABLE 6 PRICE OF IMMUNO-ONCOLOGY ASSAYS (2021)
5.5 PATENT ANALYSIS
5.6 TRADE ANALYSIS
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 7 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (TONS)
5.7 VALUE CHAIN ANALYSIS
FIGURE 22 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 23 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS OF THE IMMUNO-ONCOLOGY ASSAYS MARKET
FIGURE 24 IMMUNO-ONCOLOGY ASSAYS MARKET: ECOSYSTEM ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 IMMUNO-ONCOLOGY ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
5.11 PESTLE ANALYSIS
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 CANADA
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 JAPAN
5.12.3.2 INDIA
5.12.4 LATIN AMERICA
5.12.4.1 BRAZIL
5.12.4.2 MEXICO
5.12.5 MIDDLE EAST
5.12.6 AFRICA
5.13 TECHNOLOGY ANALYSIS
5.14 YC-YCC SHIFT
5.14.1 YC-YCC SHIFT FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET
6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
6.2 CONSUMABLES
6.2.1 RECURRENT PURCHASE OF KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 11 KEY PRODUCTS IN THE CONSUMABLES MARKET
TABLE 12 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 13 KEY PRODUCTS IN THE INSTRUMENTS MARKET
TABLE 14 IMMUNO-ONCOLOGY ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 INCREASING NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH
TABLE 15 IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019–2026 (USD MILLION)
7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 16 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
7.2.1 EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 17 IMMUNO-ONCOLOGY ASSAYS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION)
7.3 IMMUNOASSAY
7.3.1 IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER AT AN EARLY STAGE
TABLE 18 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION)
7.4 NEXT-GENERATION SEQUENCING
7.4.1 NGS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 19 IMMUNO-ONCOLOGY ASSAYS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
7.5 IN SITU HYBRIDIZATION
7.5.1 HIGH DEMAND FOR IN SITU HYBRIDIZATION IN THE DIAGNOSIS OF SMALL TUMORS TO DRIVE MARKET GROWTH
TABLE 20 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION)
7.6 FLOW CYTOMETRY
7.6.1 GROWING INCIDENCE & PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
TABLE 21 IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION)
8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION
8.1 INTRODUCTION
TABLE 22 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.2 LUNG CANCER
8.2.1 INCREASING RESEARCH ON LUNG CANCER BIOMARKERS TO DRIVE MARKET GROWTH
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 24 IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
8.3 BREAST CANCER
8.3.1 INCREASING GOVERNMENT FUNDING FOR BREAST CANCER
RESEARCH TO DRIVE MARKET GROWTH
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 26 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
8.4 COLORECTAL CANCER
8.4.1 INCREASING PREVALENCE OF COLORECTAL CANCER TO
PROPEL MARKET GROWTH
FIGURE 25 COLORECTAL CANCER INCIDENCE RATE IN KEY COUNTRIES (2018)
TABLE 27 IMMUNO-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
8.5 BLADDER CANCER
8.5.1 BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS
TABLE 28 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION, 2019–2026 (USD MILLION)
8.6 MELANOMA
8.6.1 GROWING INCIDENCE OF MELANOMA TO DRIVE THE DEMAND FOR IMMUNO-ONCOLOGY ASSAYS
TABLE 29 IMMUNO-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
8.7 OTHER CANCERS
TABLE 30 GLOBAL CANCER INCIDENCE, 2020
TABLE 31 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 32 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
9.2 RESEARCH APPLICATIONS
9.2.1 RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT TO DRIVE THE RESEARCH APPLICATIONS MARKET
TABLE 33 IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
9.3.1 BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING THEIR ADOPTION IN CLINICAL DIAGNOSTICS
TABLE 34 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 35 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 27 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
TABLE 36 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the North American immuno-
oncology assays market
TABLE 41 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 42 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 43 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 44 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 45 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives focused on promoting research to support market growth
TABLE 46 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 47 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 48 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 49 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 50 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3 EUROPE
FIGURE 28 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 51 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 55 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany to dominate the European immuno-oncology assays market during the forecast period
TABLE 56 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 57 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 58 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 59 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 60 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.2 ITALY
10.3.2.1 Increasing life science R&D in Italy to drive market growth
TABLE 61 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 62 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 63 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 64 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 65 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for research to support market growth in France
TABLE 66 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 67 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 68 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 69 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 70 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.4 UK
10.3.4.1 Growth in the country’s life science industry and increasing focus on research to propel market growth
TABLE 71 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 72 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 73 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 74 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing focus on the advancement of personalized medicine in Spain to drive market growth
TABLE 75 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 76 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 77 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 78 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 79 ROE: CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
TABLE 80 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
TABLE 81 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 82 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 83 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 84 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 30 ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
TABLE 85 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 86 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 87 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 88 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 89 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 China accounts for the largest share of the APAC market
TABLE 90 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 91 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 92 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 93 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 94 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Research initiatives toward the development of precision medicine are supporting market growth in Japan
TABLE 95 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 96 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 97 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 98 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 99 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increased demand for early cancer diagnosis to support market growth in India
TABLE 100 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 101 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 102 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 103 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 104 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 105 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040
TABLE 106 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 107 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 109 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING CONTRACT RESEARCH AND MANUFACTURING ACTIVITIES IN THE REGION TO SUPPORT MARKET GROWTH
TABLE 110 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 111 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 112 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 113 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE THE MARKET GROWTH
TABLE 114 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 31 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 32 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER (2020)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 33 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 34 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
FIGURE 35 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
11.8 COMPETITIVE SCENARIO
11.8.1 MARKET EVALUATION FRAMEWORK, 2018–2020
11.8.2 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
11.8.3 DEALS
TABLE 119 KEY DEALS
11.8.4 OTHER DEVELOPMENTS
TABLE 120 OTHER KEY DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 121 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 122 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.3 ILLUMINA, INC.
TABLE 123 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.4 MERCK MILLIPORE
TABLE 124 MERCK MILLIPORE: BUSINESS OVERVIEW
FIGURE 39 MERCK MILLIPORE: COMPANY SNAPSHOT (2020)
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 125 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
12.1.6 ABBOTT LABORATORIES, INC.
TABLE 126 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
12.1.7 SARTORIUS AG
TABLE 127 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 42 SARTORIUS AG: COMPANY SNAPSHOT (2020)
12.1.8 NANOSTRING TECHNOLOGIES, INC.
TABLE 128 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 43 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
12.1.9 HTG MOLECULAR DIAGNOSTICS, INC.
TABLE 129 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019)
12.1.10 PERKINELMER, INC.
TABLE 130 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
12.1.11 QIAGEN N.V.
TABLE 131 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
12.2 OTHER PLAYERS
12.2.1 BIOM?RIEUX SA
TABLE 132 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 47 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)
12.2.2 MYRIAD GENETICS, INC.
TABLE 133 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 48 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2019)
12.2.3 GUARDANT HEALTH, INC.
TABLE 134 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 49 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019)
12.2.4 BIO-RAD LABORATORIES, INC.
12.2.5 CHARLES RIVER LABORATORIES, INC.
12.2.6 SEEGENE INC.
TABLE 135 SEEGENE INC.: BUSINESS OVERVIEW
12.2.7 MESO SCALE DIAGNOSTICS, LLC.
TABLE 136 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
12.2.8 OLINK
12.2.9 ASURAGEN, INC.
12.2.10 INVIVOSCRIBE, INC.
12.2.11 CREATIVE BIOLABS
12.2.12 REACHBIO LLC
12.2.13 NMI TECHNOLOGIETRANSFER GMBH
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies
13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 IMMUNO-ONCOLOGY ASSAYS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 IMMUNO-ONCOLOGY ASSAYS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 4 IMMUNO-ONCOLOGY ASSAYS MARKET: BOTTOM-UP APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 IMMUNO-ONCOLOGY ASSAYS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 HEALTH ASSESSMENT
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE IMMUNO-
ONCOLOGY ASSAYS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 12 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 IMMUNO-ONCOLOGY ASSAYS MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 16 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 17 NGS SEGMENT TO GAIN MARKET SHARE BETWEEN 2021 AND 2026
4.4 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY INDICATION, 2021 VS. 2026
FIGURE 18 LUNG CANCER SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
4.5 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 19 RESEARCH APPLICATIONS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 IMMUNO-ONCOLOGY ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer and growing adoption of targeted therapies
TABLE 1 GLOBAL CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
TABLE 3 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE, 2016 VS. 2017 VS. 2018 (USD MILLION)
5.2.1.2 Increased demand for personalized medicine
TABLE 4 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018
5.2.2 RESTRAINTS
5.2.2.1 Requirement of high capital investments and low cost-benefit ratio
5.2.2.2 Unfavorable regulatory and reimbursement scenario
5.2.2.3 High cost of immunotherapy
TABLE 5 COST OF KEYTRUDA, BY COUNTRY (2018)
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets offer lucrative opportunities
5.2.3.2 Growing significance of companion diagnostics
5.2.4 CHALLENGES
5.2.4.1 Low awareness of cancer immunotherapy
5.3 IMPACT OF COVID-19 ON THE IMMUNO-ONCOLOGY ASSAYS MARKET
5.4 PRICING ANALYSIS
TABLE 6 PRICE OF IMMUNO-ONCOLOGY ASSAYS (2021)
5.5 PATENT ANALYSIS
5.6 TRADE ANALYSIS
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 7 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (TONS)
5.7 VALUE CHAIN ANALYSIS
FIGURE 22 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 23 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS OF THE IMMUNO-ONCOLOGY ASSAYS MARKET
FIGURE 24 IMMUNO-ONCOLOGY ASSAYS MARKET: ECOSYSTEM ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 IMMUNO-ONCOLOGY ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
5.11 PESTLE ANALYSIS
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 CANADA
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 JAPAN
5.12.3.2 INDIA
5.12.4 LATIN AMERICA
5.12.4.1 BRAZIL
5.12.4.2 MEXICO
5.12.5 MIDDLE EAST
5.12.6 AFRICA
5.13 TECHNOLOGY ANALYSIS
5.14 YC-YCC SHIFT
5.14.1 YC-YCC SHIFT FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET
6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
6.2 CONSUMABLES
6.2.1 RECURRENT PURCHASE OF KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 11 KEY PRODUCTS IN THE CONSUMABLES MARKET
TABLE 12 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 13 KEY PRODUCTS IN THE INSTRUMENTS MARKET
TABLE 14 IMMUNO-ONCOLOGY ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 INCREASING NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS TO SUPPORT MARKET GROWTH
TABLE 15 IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019–2026 (USD MILLION)
7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 16 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
7.2.1 EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 17 IMMUNO-ONCOLOGY ASSAYS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION)
7.3 IMMUNOASSAY
7.3.1 IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER AT AN EARLY STAGE
TABLE 18 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION)
7.4 NEXT-GENERATION SEQUENCING
7.4.1 NGS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 19 IMMUNO-ONCOLOGY ASSAYS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
7.5 IN SITU HYBRIDIZATION
7.5.1 HIGH DEMAND FOR IN SITU HYBRIDIZATION IN THE DIAGNOSIS OF SMALL TUMORS TO DRIVE MARKET GROWTH
TABLE 20 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION)
7.6 FLOW CYTOMETRY
7.6.1 GROWING INCIDENCE & PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
TABLE 21 IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION)
8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION
8.1 INTRODUCTION
TABLE 22 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.2 LUNG CANCER
8.2.1 INCREASING RESEARCH ON LUNG CANCER BIOMARKERS TO DRIVE MARKET GROWTH
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 24 IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
8.3 BREAST CANCER
8.3.1 INCREASING GOVERNMENT FUNDING FOR BREAST CANCER
RESEARCH TO DRIVE MARKET GROWTH
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 26 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
8.4 COLORECTAL CANCER
8.4.1 INCREASING PREVALENCE OF COLORECTAL CANCER TO
PROPEL MARKET GROWTH
FIGURE 25 COLORECTAL CANCER INCIDENCE RATE IN KEY COUNTRIES (2018)
TABLE 27 IMMUNO-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
8.5 BLADDER CANCER
8.5.1 BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS
TABLE 28 IMMUNO-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION, 2019–2026 (USD MILLION)
8.6 MELANOMA
8.6.1 GROWING INCIDENCE OF MELANOMA TO DRIVE THE DEMAND FOR IMMUNO-ONCOLOGY ASSAYS
TABLE 29 IMMUNO-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
8.7 OTHER CANCERS
TABLE 30 GLOBAL CANCER INCIDENCE, 2020
TABLE 31 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 32 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
9.2 RESEARCH APPLICATIONS
9.2.1 RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT TO DRIVE THE RESEARCH APPLICATIONS MARKET
TABLE 33 IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
9.3.1 BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING THEIR ADOPTION IN CLINICAL DIAGNOSTICS
TABLE 34 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 35 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 27 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
TABLE 36 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the North American immuno-
oncology assays market
TABLE 41 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 42 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 43 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 44 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 45 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives focused on promoting research to support market growth
TABLE 46 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 47 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 48 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 49 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 50 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3 EUROPE
FIGURE 28 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 51 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 55 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany to dominate the European immuno-oncology assays market during the forecast period
TABLE 56 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 57 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 58 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 59 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 60 GERMANY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.2 ITALY
10.3.2.1 Increasing life science R&D in Italy to drive market growth
TABLE 61 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 62 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 63 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 64 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 65 ITALY: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for research to support market growth in France
TABLE 66 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 67 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 68 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 69 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 70 FRANCE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.4 UK
10.3.4.1 Growth in the country’s life science industry and increasing focus on research to propel market growth
TABLE 71 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 72 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 73 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 74 UK: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing focus on the advancement of personalized medicine in Spain to drive market growth
TABLE 75 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 76 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 77 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 78 SPAIN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 79 ROE: CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
TABLE 80 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2020 VS. 2040
TABLE 81 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 82 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 83 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 84 ROE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 30 ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
TABLE 85 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 86 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 87 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 88 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 89 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 China accounts for the largest share of the APAC market
TABLE 90 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 91 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 92 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 93 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 94 CHINA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Research initiatives toward the development of precision medicine are supporting market growth in Japan
TABLE 95 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 96 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 97 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 98 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 99 JAPAN: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increased demand for early cancer diagnosis to support market growth in India
TABLE 100 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 101 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 102 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 103 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 104 INDIA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 105 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040
TABLE 106 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 107 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 109 ROAPAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING CONTRACT RESEARCH AND MANUFACTURING ACTIVITIES IN THE REGION TO SUPPORT MARKET GROWTH
TABLE 110 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 111 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 112 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 113 LATIN AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE THE MARKET GROWTH
TABLE 114 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 31 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 32 IMMUNO-ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER (2020)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 33 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 34 IMMUNO-ONCOLOGY ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
FIGURE 35 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE IMMUNO-ONCOLOGY ASSAYS MARKET
11.8 COMPETITIVE SCENARIO
11.8.1 MARKET EVALUATION FRAMEWORK, 2018–2020
11.8.2 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
11.8.3 DEALS
TABLE 119 KEY DEALS
11.8.4 OTHER DEVELOPMENTS
TABLE 120 OTHER KEY DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 121 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 122 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.3 ILLUMINA, INC.
TABLE 123 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.4 MERCK MILLIPORE
TABLE 124 MERCK MILLIPORE: BUSINESS OVERVIEW
FIGURE 39 MERCK MILLIPORE: COMPANY SNAPSHOT (2020)
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 125 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
12.1.6 ABBOTT LABORATORIES, INC.
TABLE 126 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
12.1.7 SARTORIUS AG
TABLE 127 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 42 SARTORIUS AG: COMPANY SNAPSHOT (2020)
12.1.8 NANOSTRING TECHNOLOGIES, INC.
TABLE 128 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 43 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
12.1.9 HTG MOLECULAR DIAGNOSTICS, INC.
TABLE 129 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019)
12.1.10 PERKINELMER, INC.
TABLE 130 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
12.1.11 QIAGEN N.V.
TABLE 131 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
12.2 OTHER PLAYERS
12.2.1 BIOM?RIEUX SA
TABLE 132 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 47 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)
12.2.2 MYRIAD GENETICS, INC.
TABLE 133 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 48 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2019)
12.2.3 GUARDANT HEALTH, INC.
TABLE 134 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 49 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019)
12.2.4 BIO-RAD LABORATORIES, INC.
12.2.5 CHARLES RIVER LABORATORIES, INC.
12.2.6 SEEGENE INC.
TABLE 135 SEEGENE INC.: BUSINESS OVERVIEW
12.2.7 MESO SCALE DIAGNOSTICS, LLC.
TABLE 136 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
12.2.8 OLINK
12.2.9 ASURAGEN, INC.
12.2.10 INVIVOSCRIBE, INC.
12.2.11 CREATIVE BIOLABS
12.2.12 REACHBIO LLC
12.2.13 NMI TECHNOLOGIETRANSFER GMBH
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies
13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
